Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 6 people enrolled
- Started
- 1 Oct 2021
- Ended
- 1 Aug 2024
- Type of study
- Interventional
- Treatments tested
- RoadMAB precision dashboard
- Infliximab precision dosing
- Record updated
- 11 March 2026
- Why it stopped
- This was the Pilot study. The larger, confirmatory study has started
Who can take part
- Age
- 6 years to 22 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Written informed consent form from the patient (≥18 years old) or from parent/legal guardian if patient is <18 years old
- Written informed assent form from patient ≥11 years old
- Age criteria: ≥6 years to ≤22 years of age
- Diagnosis of Crohn's Disease
- Starting infliximab (or biosimilar)
- Anti-TNF naïve (never received infliximab, adalimumab, golimumab, certolizumab or anti-TNF biosimilar)
- Fecal calprotectin >250 µg/g or fecal lactoferrin >10 µg/g (up to 6 weeks prior to starting infliximab) or endoscopic evidence of active Crohn's disease (up to 90 days prior to starting infliximab)
- wPCDAI >12.5 (up to 6 weeks) prior to the first infliximab infusion
- Negative urine pregnancy test for ALL female subjects
- Negative TB (tuberculosis) blood test
Who cannot take part
- Prior treatment with infliximab, adalimumab, certolizumab or golimumab (or anti-TNF biosimilar)
- Active or prior evidence in past 12 months of internal (abdominal/pelvic) penetrating fistula(e)
- Current ileostomy, colostomy, ileoanal pouch, and/or previous extensive small bowel resection leading to short bowel syndrome
- Treatment with another investigational drug within four weeks
- Treatment with intravenous antibiotics within four weeks
- Treatment with intravenous corticosteroids within two weeks
- Diagnosis of ulcerative colitis or inflammatory bowel disease-unspecified
- Active Clostridium difficile infection or other known bacterial/viral gastroenteritis in last two weeks
- History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis)
- Inability or failure to provide informed assent/consent
- Active intestinal stricture (luminal narrowing with pre-stenotic dilation >3mm), intra-abdominal abscess or perianal abscess
- Planned continuation of 6-mercaptopurine or azathioprine (Imuran) during study
- Planned continuation of methotrexate during study
- Currently pregnant, breast feeding or plans in next 12 months to become pregnant
Where in United States
- Cincinnati Children's HospitalCincinnati, United States
About the trial
What the trial wants to find out
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents. Physicians need better ways to inform decisions on treatment.
Read full original descriptionShow less
The main reason for this research study is to determine if a computer program that formulates a dose based on a patient's blood testing results can better achieve the optimal drug level as compared to standard dosing.
The group in the trial
- Interventional arm with precision dosingTreatment being tested
The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
Treatment: RoadMAB precision dashboard and Infliximab precision dosing
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 11 March 2026